Depletion of IL-10- and TGF-β-producing regulatory γδ T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells

Journal of Immunology

Volumn 163, Issue 1, 1999, Pages 242-249

  Seo, Naohiro ^a,b,c   Tokura, Yoshiki ^b   Takigawa, Masahiro ^b   Egawa, Kohji ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Tumor Laboratory   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN CONJUGATED SPECIFIC MONOCLONAL ANTIBODY; DAUNORUBICIN DERIVATIVE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; MESSENGER RNA; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER REGRESSION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; IMMUNOSTIMULATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATUMORAL DRUG ADMINISTRATION; LYMPHOCYTE DEPLETION; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE SUBPOPULATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CARCINOMA, HEPATOCELLULAR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DAUNORUBICIN; INTERLEUKIN-10; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SUPPRESSOR FACTORS, IMMUNOLOGIC; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0033168162     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Maeda, H., and A. Shiraishi. 1996. TGF-β contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J. Immunol. 156:73.
2. Maeda, H., H. Kuwahara, Y. Ichimura, M. Ohtsuki, S. Kurakata, and A. Shiraishi. 1995. TGF-β enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J. Immunol. 155:4926.
3. Yamamoto, N., J. P. Zou, X. F. Li, H. Takenaka, S. Noda, T. Fujii, S. Ono, Y. Kobayashi, N. Mukaida, and K. Matsushima. 1995. Regulatory mechanisms for production of IFN-γ and TNF by antitumor T cells or macrophages in the tumor-bearing state. J. Immunol. 154:2281.
4. Kondo, S., M. Asano, K. Matsuo, I. Ohmori, and H. Suzuki. 1994. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim. Biophys. Acta 122:211.
5. + T cells subset inhibits antigen-specific T cell responses and prevents colitis. Nature 389:737.
6. Mao, X. W., J. D. Kettering, and D. S. Gridley. 1994. Immunotherapy with low-dose interleukin-2 and anti-transforming growth factor-β Ab in a murine tumor model. Cancer Biother. 9:317.
7. Gridley, D. S., S. S. Sura, J. R. Uhm, C. H. Lin, and J. D. Kettering. 1993. Effects of anti-transforming growth factor-β Ab and interleukin-2 in tumor-bearing mice. Cancer Biother. 8:159.
8. Dunn, P. L., and R. J. North. 1991. Effect of advanced aging on ability of mice to cause regression of an immunogenic lymphoma in response to immunotherapy based on depletion of suppressor T cells. Cancer Immunol. Immunother. 33:421.
9. Field, E. H., T. M. Rouse, A. L. Fleming, I. Jamali, and J. S. Cowdery. 1992. Altered IFN-γ and IL-4 pattern lymphokine secretion in mice partially depleted of CD4 T cells by anti-CD4 monoclonal Ab. J. Immunol. 149:1131.
10. + T cells in vivo. J. Exp. Med. 173:1463.
11. + T cells. Immunology 87:29.
12. + αβ T cells is required for the avian γδ T cell response. Eur. J. Immunol. 23:2034.
13. Schaffar, L., A. Dallanegra, J. P. Breittmayer, S. Carrel, and M. Fehlmann. 1988. Monoclonal Ab internalization and degradation during modulation of the CD3/ T-cell receptor complex. Cell. Immunol. 116:52.
14. Bluestone, J. A., and C. Lopez. 1979. Suppression of the immune response in tumor-bearing mice. I. Response to virus-producing tumor cells and non-virus-producing tumor cells. J. Natl. Cancer Inst. 63:1215.
15. Farrar, W. L., K. D. Elgert, and A. S. Foo. 1981. Suppressor cell activity in tumor-bearing mice. III. Co-purification of a factor inhibiting cellular DNA synthesis and DNA polymerase activity. J. Immunol. 127:2339.
16. Gallego, J., M. R. Price, and R. W. Baldwin. 1984. Preparation of four daunomycin-monoclonal Ab 791T/36 conjugates with anti-tumour activity. Int. J. Cancer 33:737.
17. Levy, R., E. Hurwitz, R. Maron, R. Arnon, and M. Sela. 1975.The specific cytotoxic effects of daunomycin conjugated to antitumor Abs. Cancer Res. 35:1182.
18. Seo, N., and K. Egawa. 1995. Suppression of cytotoxic T lymphocyte activity by γ/δ T cells in tumor-bearing mice. Cancer Immunol. Immunother. 40:358.
19. b molecules expressed on Th2-type γδ T and αβ T cells co-infiltrating in early B16 melanoma lesions. J. Immunol. 161:4138.
20. + T cells and induces the synthesis of IL-3 and IFN-γ but not IL-4 or IL-6. Int. Immunol. 4:475.
21. Enk, A. H., and S. I. Katz. 1992. Identification and induction of keratinocyte-derived IL-10. J. Immunol. 149:92.
22. Rugo, H. S., P. O'Hanley, A. G. Bishop, M. K. Pearce, J. S. Abrams, M. Howard, and A. O'Garra. 1992. Local cytokine production in a murine model of Escherichia coli pyelonephritis. J. Clin. Invest. 89:1032.
23. Seo, N., and Y. Tokura. 1999. Down-regulation of innate and acquired anti-tumor immunity by bystander γδ and αβ T Lymphocytes with Th2 or Tr1 cytokine profile. J. Interferon Cytokine Res. In press.
24. Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145.
25. Asseman, C., and F. Powrie. 1998. Interleukin 10 is a growth factor for a population of regulatory T cells. Gut 42:157.
26. Kanto, T., T. Takehara, K. Katayama, A. Ito, K. Mochizuki, N. Kuzushita, T. Tatsumi, Y. Sasaki, A. Kasahara, N. Hayashi, et al. 1997. Neutralization of transforming growth factor β1 augments hepatitis C virus-specific cytotoxic T lymphocyte induction in vitro. J. Clin. Immunol. 17:462.
27. Rowley, D. A., E. T. Becken, and R. M. Stach. 1995. Autoantibodies produced spontaneously by young lpr mice carry transforming growth factor β and suppress cytotoxic T lymphocyte responses. J. Exp. Med. 181:1875.
28. Zheng, L. M., D. M. Ojcius, F. Garaud, C. Roth, E. Maxwell, Z. Li, H. Rong, J. Chen, X. Y. Wang, J. J. Catino, et al. 1996. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J. Exp. Med. 184:579.
29. Tsuruma, T., A. Yagihashi, T. Torigoe, N. Sato, K. Kikuchi, N. Watanabe, and K. Hirata. 1998. Interleukin-10 reduces natural killer sensitivity and downregulates MHC class I expression on H-ras-transformed cells. Cell. Immunol. 184:121.
30. Nguyen, T. D., M. J. Smith, and P. Hersey. 1997. Contrasting effects of T cell growth factors on T cell responses to melanoma in vitro. Cancer Immunol. Immunother. 43:345.
31. Yang, G., K. E. Hellstrom, M. T. Mizuno, and L. Chen. 1995. In vitro priming of tumor-reactive cytotoxic T lymphocytes by combining IL-10 with B7-CD28 costimulation. J. Immunol. 155:1897.
32. Giovarelli, M., P. Musiani, A. Modesti, P. Dellabona, G. Casorati, A. Allione, M. Consalvo, F. Cavallo, F. di Pierro, C. De Giovanni, et al. 1995. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and Ab-dependent immune memory. J. Immunol. 155:3112.
33. Ericsson, P. O., J. Hansson, B. Widegren, M. Dohlsten, H. O. Sjogren, and G. Hedlund. 1991. In vivo induction of γ/δ T cells with highly potent and selective anti-tumor cytotoxicity. Eur. J. Immunol. 21:2797.
34. Fisch, P., M. Malkovsky, E. Braakman, E. Sturm, R. L. Bolhuis, A. Prieve, J. A. Sosman, V. A. Lam, and P. M. Sondel. 1990. γ/δ T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis. J. Exp. Med. 171:1567.
35. Gan, Y. H., and M. Malkovsky. 1996. Mechanisms of simian γδ T cell cytotoxicity against tumor and immunodeficiency virus-infected cells. Immunol. Lett. 49:191.
36. Ruzek, M. C., and A. Mathur. 1995. Specific decrease of Th1-like activity in mice with plasma cell tumors. Int. Immunol. 7:1029.
37. Hein, W. R., and C. R. Mackay. 1991. Prominence of γδ T cells in the ruminant immune system. Immunol. Today 12:30.
38. + T cells. Immunology 81:27.
39. Mincheva-Nilsson, L., M. Kling, S. Hammarstrom, O. Nagaeva, K. G. Sundqvist, M. L. Hammarstrom, and V. Baranov. 1997. γδ T cells of human early pregnancy decidua: evidence for local proliferation, phenotypic heterogeneity, and extrathymic differentiation. J. Immunol. 159:3266.
40. Abo, T. 1993. Extrathymic pathways of T-cell differentiation: a primitive and fundamental immune system. Microbiol. Immunol. 37:247.
41. Pierson, B. A., K. Gupta, W. S. Hu, and J. S. Miller. 1996. Human Natural killer cell expansion is regulated by thrombospondin-mediated activation of transforming growth factor-β-1 and independent accessory cell-derived contact and soluble factors. Blood 87:180.
42. Ma, D., and J. Y. Niederkorn. 1995. Transforming growth factor-β down-regulates major histocompatibility complex class 1 antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology 86:263.
43. Salazar-Onfray, F., J. Charo, M. Petersson, S. Freland, G. Moffz, Z. Qin, T. Blankenstein, H. G. Ljunggren, and R. Kiessling. 1997. Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J. Immunol. 159:3195.
44. Kurosawa, S., M. Harada, G. Matsuzaki, Y. Shinomiya, H. Terao, N. Kobayashi, and K. Nomoto. 1995. Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes. Immunology 85:338.
45. Tsukada, Y., K. Ohkawa, and N. Hibi. 1987. Therapeutic effect of treatment with polyclonal or monoclonal Abs to α-fetoprotein that have been conjugated to daunomycin via a dextran bridge: studies with an α-fetoprotein-producing rat hepatoma tumor model. Cancer Res. 47:4293.
46. Hurwitz, E., R. Maron, A. Bernstein, M. Wilchek, M. Sela, and R. Arnon. 1978. The effect in vivo of chemotherapeutic drug-Ab conjugates in two murine experimental tumor systems. Int. J. Cancer 21:747.
47. Bernstein, A., E. Hurwitz, R. Maron, R. Arnon, M. Sela, and M. Wilchek. 1978. Higher antitumor efficacy of daunomycin when linked to dextran: in vivo and in vitro studies. J. Natl. Cancer Inst. 60:379.
48. Monaco, M. E., J. Mack, M. D. Dugan, and R. Ceriani. 1986. An Ab-toxin conjugate directed against a human mammary cancer antigen. Ann. NY Acad. Sci. 464:389.
49. Bernhard, M. I., K. A. Foon, T. N. Oeltmann, M. E. Key, K. M. Hwang, G. C. Clarke, W. L. Christensen, L. C. Hoyer, M. G. Hanna, Jr., and R. K. Oldham. 1983. Guinea pig line 10 hepatocarcinoma model: characterization of monoclonal Ab and in vivo effect of unconjugated Ab and Ab conjugated to diphtheria toxin A chain. Cancer Res. 43:4420.
50. Byers, V. S., R. Rodvien, K. Grant, L. G. Durrant, K. H. Hudson, R. W. Baldwin, and P. J. Scannon. 1989. Phase 1 study of monoclonal Ab-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer. Cancer Res. 49:6153.
51. Weiner, L. M., J. O'Dwyer, J. Kitson, R. L. Comis, A. E. Frankel, R. J. Bauer, M. S. Konrad, and E. S. Groves. 1989. Phase I evaluation of an anti-breast carcinoma monoclonal Ab 260F9-recombinant ricin A chain immunoconjugate. Cancer Res. 49:4062.